Abstract:Introduction: The management of soft tissue sarcomas presents considerable therapeutic challenges. This study was designed to assess the efficacy of neoadjuvant sequential chemotherapy and hypofractionated radiotherapy in conjunction with extensive surgical resection for the treatment of high-risk soft tissue sarcomas. Materials and methods: We performed a retrospective review of 31 high-risk soft tissue sarcoma patients treated at our institution from June 2021 to June 2023. The cohort consisted of 21 males and 10 females with a mean age of 55.7 years and included both initial and recurrent disease presentations. Our treatment regimen comprised two to three cycles of neoadjuvant chemotherapy coupled with hypofractionated radiotherapy, delivered at 5 Gy per fraction to a total dose of 25–35 Gy across 5–7 days, prior to surgical resection aimed at achieving wide margins. Data collection was systematic, covering surgical outcomes, chemoradiotherapy-related complications, and prognostic factors. Results: All patients completed the prescribed course of neoadjuvant chemoradiotherapy. 29% patients experienced grade 3+ chemotherapy toxicity, necessitating a reduction or interruption in their chemotherapy regimen. Limb preservation was accomplished in 30 patients finally. Response evaluation using RECIST 1.1 criteria post-neoadjuvant therapy revealed 9.7% with PD, 58.1% with SD, 29% with a PR, and 3.2% with a CR, culminating in an ORR of 32.2%. Postoperative complications included superficial wound infections in four patients and deep incisional infections in another four. 6 patients had developed metastasis, and 3 patients were still alive. Two experienced local recurrence. One-year DFS was 79.3%, with a one-year OS rate of 89.6%. Conclusion: Neoadjuvant sequential chemotherapy and hypofractionated radiotherapy followed by extensive surgical resection represents an effective treatment paradigm for high-risk soft tissue sarcomas. This multimodal approach not only facilitates tumor reduction but also significantly reduces the risks of local recurrence and distant metastasis.

The Clinical Research Advance of New Drugs in Soft Tissue Sarcoma

The standard treatments and advance of medication in soft-tissue sarcomas

Clinical prospect of research on molecular targeted therapy in soft tissue sarcomas

Treatment of advanced soft tissue sarcoma: opportunity and challenge

[Progress in the treatment of soft tissue sarcoma in the 2023 annual meeting of the American Society of Clinical Oncology]

Advances in therapy of sarcoma of soft tissue

Advances of Systemic Treatment for Adult Soft-Tissue Sarcoma

Advances in molecular targeted therapy for soft tissue sarcomas

Chemotherapeutic drugs for soft tissue sarcomas: a review

Clinical Analysis of 251 Cases of Soft Tissue Sarcomas

Present situation of research on radiotherapy of adult soft tissue sarcoma

Progression in anti-angiogenesis agents for soft tissue sarcoma

New strategies in soft tissue sarcoma treatment

Stereotactic Body Radiotherapy for Metastatic and Recurrent Soft Tissue Sarcoma

Significance Of Local Treatment In Patients With Metastatic Soft Tissue Sarcoma

Advances in Clinical Research on Soft Tissue Clear Cell Sarcoma

The role of neoadjuvant radiochemotherapy in the management of localized high-grade soft tissue sarcoma

Diagnosis and treatment of soft tissue sarcomas:hot and difficult problems

Clinical analysis of 122 cases of soft tissue sarcoma of the extremity

Clinical Features and Prognosis of 25 Cases of Soft Tissue Sarcoma with Soft Tissue Me-Tastasis

Preoperative sequential chemotherapy and hypofractionated radiotherapy combined with comprehensive surgical resection for high-risk soft tissue sarcomas: a retrospective study